We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$407M
AUM Growth
-$38.3M
Cap. Flow
-$52.4M
Cap. Flow %
-12.88%
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$6.14M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$5.93M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.36M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.07M
5
ZYME icon
Zymeworks
ZYME
+$808K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.83M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.57M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.53M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$966K

Sector Composition

Rank Sector Weight
1 Industrials 19.96%
2 Technology 18%
3 Healthcare 15.75%
4 Materials 7.84%
5 Financials 7.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAVG
201
DELISTED
Navigators Group Inc
NAVG
– –
-9,997
Closed -$570K
LJPC
202
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-156,562
Closed -$4.57M
5 6 7 8
9

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q3 2018 Portfolio in Review

As of Q3 2018, Stanley-Laman Group held 282 positions worth $407M, down 8.6% from $445M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Stanley-Laman Group withdrew a net $52.4M in Q3 2018, closing 63 positions and reducing 110 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $8.83M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stanley-Laman Group opened a new position in Acceleron Pharma worth $7.16M.

  • Stanley-Laman Group's largest Q3 2018 buy was Acceleron Pharma: 125,020 shares worth $7.16M.
  • Stanley-Laman Group added most to Prudential Financial in Q3 2018, an estimated $152K increase.
  • Stanley-Laman Group's biggest Q3 2018 reduction was Hortonworks, Inc., cutting an estimated $629K.
  • Stanley-Laman Group fully exited Neurocrine Biosciences in Q3 2018, selling an estimated $8.83M.
  • Stanley-Laman Group's ten largest holdings make up 19% of its $407M portfolio in Q3 2018.
  • Stanley-Laman Group opened 19 new positions and closed 63 in Q3 2018.
  • Stanley-Laman Group's portfolio value fell 8.6% quarter-over-quarter to $407M.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.